Black Diamond Therapeutics
BDTX
109 hedge funds and large institutions have $915M invested in Black Diamond Therapeutics in 2020 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 43 increasing their positions, 11 reducing their positions, and 12 closing their positions.
291% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 11
175% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 12
28% more capital invested
Capital invested by funds: $717M → $915M (+$198M)
24% more funds holding
Funds holding: 88 → 109 (+21)
13.2% more ownership
Funds ownership: 66.17% → 79.37% (+13%)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$19.9M |
| 2 |
BlackRock
New York
|
+$18.9M |
| 3 |
State Street
Boston,
Massachusetts
|
+$17.9M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$10.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$4.4M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.14M |
| 3 |
SG Americas Securities
New York
|
-$1.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$817K |
| 5 |
TC
Telemus Capital
Southfield,
Michigan
|
-$506K |
BDTX Hedge Fund Activity: Q4 2020 in Review
109 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q4 2020, worth a combined $915M — up 28% from $717M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new BDTX positions and 12 closed out — a net gain of 21 holders — while 43 added to existing stakes and 11 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $19.9M. The largest seller was Vivo Capital, exiting entirely with an estimated $4.4M sold.
- 109 institutional investors held Black Diamond Therapeutics (BDTX) as of Q4 2020, up from 88 in Q3 2020.
- Funds reported $915M of Black Diamond Therapeutics stock for Q4 2020, up 28% quarter-over-quarter.
- 33 funds opened new Black Diamond Therapeutics positions in Q4 2020 and 12 closed out, a net change of +21 holders.
- The largest Black Diamond Therapeutics buyer in Q4 2020 was Point72 Asset Management, an estimated $19.9M added.
- The largest Black Diamond Therapeutics seller in Q4 2020 was Vivo Capital, an estimated $4.4M sold.
Based on aggregated 13F filings for Q4 2020.